CDK4/6 inhibitor selection eLearning
Barbara, Juanita and Emma have all been diagnosed with HR+/HER2- metastatic breast cancer and have been prescribed a CDK4/6 inhibitor. Can you help us select the optimal CDK4/6 inhibitor for each of our three patients?
CDK4/6 inhibitor selection eLearning
The ‘CDK4/6 inhibitor selection’ interactive eLearning module covers the rationale for choosing one CDK4/6 inhibitor over another, for each of our three metastatic breast cancer patients.
| Section outline | Content outline | Time (20 mins total) |
| Section 1 | Overview | 5 mins |
| Section 2 | Patient Case: Barbara | 5 mins |
| Patient Case: Juanita | 5 mins | |
| Patient Case: Emma | 5 mins |
Course overview
This interactive ‘CDK4/6 inhibitor selection’ eLearning module was developed together with Dr Gregory Vidal, a medical oncologist and researcher from the West Cancer Center and Research Institute, USA. Using three example patient case studies, the module highlights the key differences between abemaciclib, palbociclib and ribociclib that may impact the choice of CDK4/6 inhibitor for your patient. Some differentiators discussed include:
- disease characteristics (for example, central nervous system and visceral involvement)
- patient characteristics (menopausal status and other health issues)
- safety and tolerance (adverse events and monitoring)
Faculty
Dr Gregory Vidal, MD, PhD, is a Medical Oncologist at West Cancer Center and Research Institute and Assistant Professor at the University of Tennessee Health Science Center, USA. Dr Vidal trained as a clinical researcher at the University of Stanford, and the aim of his research is to discover and develop safe and effective treatments for breast cancer.
Further information
For more information on selecting the optimal CDK4/6 inhibitor for your patient, visit our pages on CDK4/6 inhibitor selection, where you will also find expert video interviews on the topic.
CDK4/6 inhibitor selection eLearning
The ‘CDK4/6 inhibitor selection’ interactive eLearning module covers the rationale for choosing one CDK4/6 inhibitor over another, for each of our three metastatic breast cancer patients.
of interest
are looking at
saved
next event
This activity is supported by an educational grant from Eli Lilly and Company, this content has been developed by IMR International (Australia) independently of the sponsor Eli Lilly, who have had no editorial input into the content. IMR International (Australia) received unrestricted educational funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.